Stock is consolidating above R4 camarilla levels in weekly time frame.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。